Data & Insights

Patient Journeys

  • Therapeutic switching

    For clinicians, a deeper understanding of how patients respond to various treatments over time facilitates personalized care and informed decision-making for subsequent lines of therapy. For novel oncology therapeutics, the availability of onco-biomarkers and knowledge of genetic mutations is particularly important in guiding decisions on treatment switching. Structured data from one or multiple patient journeys provide valuable insights into the potential benefits and harms of novel treatment-switching patterns. 

  • Sample sizes top-up

    Comparative effectiveness studies sourcing patient medical records often fall short on sample size. A combination of multiple data sources is widely accepted for augmenting study precision. OpenCase provides easy searches, views, and selections of patient journeys, and allows quick downloads of analysis-ready datasets for study-eligible patients. 

  • Novel off-label treatments

    The last decades have demonstrated that drug classes initially indicated for one type of cancer also confer benefit in another. Yet, the efficacy and safety of many novel agents are only backed up by clinical trials for one or few indications. Complete patient journey data including off-label use of novel treatment can provide early insights for planning and designing further studies and ultimately broaden the span of drug indications.

  • Identification of rare events  

    Clinical trials often miss unsuspected rare adverse events or do not have sufficient sample sizes to capture rare events. In addition, drug-related safety signals for novel therapeutics can also present several months or years after treatment completion and are therefore difficult to capture both in clinical trials and the real world without highly diligent patient follow-up. OpenCase data allows rapid identification of event outliers for the clinician and regulatory follow-up 

Pharmacovigilance + Tolerability

There has been no systematic way of capturing accurate pharmacovigilance and tolerability data on case reports on oncology therapeutics… until now.

The Opportunity:

Of all types of real-world evidence, case reports are particularly rich in information. Case reports:

  • are often the first to identify rare or previously undocumented adverse events;

  • frequently identify reports of serious or life-threatening adverse events;

  • provide detailed descriptions of adverse events;

  • are clinician-adjudicated for drug causality;

  • document the full patient journey;

  • Includes sufficiently long follow-up to capture treatment-related tolerability issues after treatment has been terminated

Data Aggregation

We provide valuable insights to facilitate the adoption and utilization of innovative healthcare solutions.

With structured data from over 60,000 case reports documenting the journeys of oncology patients, we offer comprehensive analyses on alternative treatment approaches, biomarker-guided therapeutic options, transitions between therapies, patient tolerability, and significant clinical occurrences in cancer cases.

We empower healthcare stakeholders with the essential knowledge for making informed decisions and optimizing patient care strategies.

Bespoke NLP

We offer bespoke natural language processing (NLP) and artificial intelligence (AI) solutions for extracting structured and meaningful data from large collections of complex medical text.

Our solutions substantially reduce the manual work required by clinical curators and researchers. 

We also develop bespoke tools and APIs to fit within the platforms that our clients are working from.